Explore more publications!

Tech Daily Missouri: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Missouri.

Press releases published on March 24, 2026

Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
Serina Therapeutics to Present at the 38th Annual Roth Conference
Zymeworks Announces Participation in Upcoming Investor Conferences
Andromeda Shatters Identity Silos with the Industry’s First Unified Security Architecture for the Agentic Workforce
Yatiri Bio Enters Exclusive Option to In-License Agreement with Oscotec for Denfivontinib in AML
Jiayin Group Inc. to Release Fourth Quarter and Full Year 2025 Unaudited Financial Results on Tuesday, March 31, 2026
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
Mach Industries Selects Nominal to Run Test Infrastructure for Its Next-Generation Strike and Surveillance Systems
Nature Translational Psychiatry Study Reveals Distinct Functional Neuronal Signatures in Patient-Derived Brain Organoids with Itay&Beyond’s Neurotech Platform
ONERugged Vehicle-Mounted Computer V82T Launches to Transform Fleet Management
Connecting the World, Driving Apex Growth: Apexmind Summit 2026 Successfully Held in HongKong
Micro, AMFI and CEiiA Join Forces to create the next generation microcars and industrialize BEN in Turin
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
SUSE Advances Intelligent Infrastructure Management with Latest AI and Virtualization Updates
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
Press release: Availability of the Q1 2026 aide-mémoire
Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse  

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions